General
publicado em 02/01/2013 às 15h38:00
   Dê o seu voto:

Anvisa should publish this month new analysis on the use of sibutramine

Authority must decide whether to maintain authorization for use of the drug in the country. In 2011, the agency decided to ban slimming

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



The National Health Surveillance Agency (ANVISA) to publish this month a new analysis on the use of sibutramine in the Brazilian market. The court must decide whether to maintain the authorization for the use of the drug in the country.

In 2011, the agency decided to banish the slimming-based amfepramone femproporex and mazindol, called amphetamines. Already released sibutramine remained, but with restrictions. Patients and physicians must sign a liability release, which must be submitted along with the recipe at the time of purchase. Health professionals are also required to inform the Anvisa problems presented by patients.

The initial proposal was for technical agency in the country to ban the drug because international studies show that substance use increases the risk of cardiovascular problems and changes in the central nervous system. But after nine months of debate, the crew shifted and, in the last report, defended the stay of the sale and use of the medicine in Brazil. Within one year, the agency would again consider the maintenance of sibutramine in the Brazilian market.

According to Anvisa, sibutramine helps lose at least 2 pounds of body weight for a period of four weeks. Treatment is indicated for those with body mass index (BMI) equal to or above 30 and not have heart disease. The maximum use of the drug is two years.

Since the announcement of the proposal to take the slimming market, medical societies were against the idea. The Brazilian Association for the Study of Obesity (ABESO) argues that without these drugs, patients are obese with no possibility of treatment.

Source: AGÊNCIA BRASIL
   Palavras-chave:   Sibutramine    Slimming    ANVISA    The National Agency for Sanitary Vigilance    Medicine   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Anvisa should publish this month new analysis on the use of sibutramine
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Anvisa should publish this month new analysis on the use of sibutramine


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
sibutramine    slimming    ANVISA    the National Agency for Sanitary Vigilance    medicine   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.